Candel Therapeutics Inc
NASDAQ:CADL
Intrinsic Value
Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CADL.
Candel Therapeutics Inc's market capitalization is 158.8m USD.
CADL stock price is 5.46 USD.
CADL.
CADL. Open DCF Valuation
CADL. Open Relative Valuation
CADL has upside potential of 105% compared to the average analyst price target.
Open Wall St Estimates
CADL's D/E (Debt to Equity) is very low and is equal to 0.97.
CADL's long-term assets (41m USD) exceed its long-term liabilties (28m USD).
CADL's ROE (Return on Equity) has significantly decreased in the last 3 years from -94% to -126%, and is approaching profitability.
CADL's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -367% to -605%, and is approaching profitability.
CADL has negative Operating Income for the last twelve months.
CADL has negative Net Income for the last twelve months.
CADL's ROE (Return on Equity) for the past 12 months is negative and is equal to -126%.
CADL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -605%.
CADL's short-term assets (37m USD) exceed its short-term liabilties (14m USD).
CADL has negative Net Debt. This means that the company has more cash and short-term investments (35m USD) than debt (12m USD).
CADL has negative Free Cash Flow for the last twelve months.
CADL has negative three-year average ROE (Return on Equity): -103%. The company is not efficient at transforming stockholders' equity into net income.
CADL has negative three-year average ROIC (Return on Invested Capital): -476%. The company is not efficient at using invested capital to generate operating income.
CADL's Altman Z-Score is very low and is equal to -7.17.
CADL doesn't generate enough operating income (-38m USD) to safely cover interest payments on its debt (2m USD).
Fundamental Analysis
Candel Therapeutics Inc
Balance Sheet Decomposition
Candel Therapeutics Inc
| Current Assets | 36.8m |
| Cash & Short-Term Investments | 35.4m |
| Other Current Assets | 1.4m |
| Non-Current Assets | 4.4m |
| PP&E | 4m |
| Other Non-Current Assets | 382k |
| Current Liabilities | 14.2m |
| Accounts Payable | 422k |
| Accrued Liabilities | 4.9m |
| Other Current Liabilities | 8.9m |
| Non-Current Liabilities | 14.3m |
| Long-Term Debt | 12.4m |
| Other Non-Current Liabilities | 1.9m |
Earnings Waterfall
Candel Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-38m
USD
|
|
Operating Income
|
-38m
USD
|
|
Other Expenses
|
52k
USD
|
|
Net Income
|
-37.9m
USD
|
Free Cash Flow Analysis
Candel Therapeutics Inc
What is Free Cash Flow?
CADL Profitability Score
Profitability Due Diligence
Candel Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Candel Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
CADL Solvency Score
Solvency Due Diligence
Candel Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Candel Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CADL Price Targets Summary
Candel Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CADL
is 11.22 USD
with a low forecast of 11.11 USD and a high forecast of 11.55 USD.
Ownership
CADL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CADL Price
Candel Therapeutics Inc
| Average Annual Return | -31.8% |
| Standard Deviation of Annual Returns | 65.17% |
| Max Drawdown | -94% |
| Market Capitalization | 158.8m USD |
| Shares Outstanding | 28 919 800 |
| Percentage of Shares Shorted | 0.82% |
Company Profile
Candel Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. The company is headquartered in Needham, Massachusetts and currently employs 50 full-time employees. The company went IPO on 2021-07-27. The firm is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The firm also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its preclinical models and clinical trials use its approach.
You don't have any saved screeners yet
